Gemini Therapeutics, Inc. (GMTX)
NASDAQ: GMTX · IEX Real-Time Price · USD
1.76
-0.17 (-8.81%)
Aug 12, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Selling, General & Admin
|
20.29 | 5.87 | 6.75 |
| Research & Development
|
48.72 | 28.17 | 34.47 |
| Operating Expenses
|
69 | 34.04 | 41.23 |
| Operating Income
|
-69 | -34.04 | -41.23 |
| Interest Expense / Income
|
2.16 | 6.83 | 0.35 |
| Other Expense / Income
|
0.71 | -0.03 | -0.18 |
| Pretax Income
|
-71.87 | -40.84 | -41.4 |
| Net Income
|
-71.87 | -40.84 | -41.4 |
| Net Income Common
|
-71.87 | -40.84 | -41.4 |
| Shares Outstanding (Basic)
|
40 | 15 | 5 |
| Shares Outstanding (Diluted)
|
40 | 15 | 5 |
| Shares Change
|
167.03% | 192.28% | - |
| EPS (Basic)
|
-1.78 | -2.70 | -8.01 |
| EPS (Diluted)
|
-1.78 | -2.70 | -8.01 |
| Free Cash Flow Per Share
|
-1.47 | -2.17 | -7.50 |
| EBITDA
|
-69.48 | -33.69 | -40.76 |
| Depreciation & Amortization
|
0.23 | 0.32 | 0.29 |
| EBIT
|
-69.71 | -34.01 | -41.05 |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).